NasdaqCM - Nasdaq Real Time Price USD

ProPhase Labs, Inc. (PRPH)

0.3270
+0.0240
+(7.92%)
At close: May 12 at 4:00:00 PM EDT
0.3300
+0.00
+(0.92%)
After hours: May 12 at 7:46:47 PM EDT
Loading Chart for PRPH
  • Previous Close 0.3030
  • Open 0.3046
  • Bid --
  • Ask --
  • Day's Range 0.3000 - 0.3300
  • 52 Week Range 0.2200 - 5.4500
  • Volume 580,993
  • Avg. Volume 8,040,740
  • Market Cap (intraday) 13.694M
  • Beta (5Y Monthly) -0.46
  • PE Ratio (TTM) --
  • EPS (TTM) -2.4200
  • Earnings Date May 13, 2025 - May 22, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date May 24, 2022
  • 1y Target Est 13.80

ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of dietary supplements under the TK supplements, including Legendz XL, a male sexual enhancement; and Triple Edge XL, an energy and stamina booster. It also develops BE-Smart Esophageal Pre-Cancer diagnostics screening test for early detection of esophageal cancer; genomics testing technologies to analyze entire genomes, including the genes and chromosomes in deoxyribonucleic acid; DNA Expand, a platform that allows consumers to upload their DNA data from previous DNA tests obtained from other service providers; and LB-1 and LB-2 for the treatment of cancer, inflammatory diseases or symptoms and memory related syndromes, diseases or symptoms, including dementia and Alzheimer's disease. In addition, the company provides a broad range of COVID-19 related clinical diagnostic and testing services, comprising PCR testing for COVID-19, and Influenza A and B, as well as rapid antigen testing for COVID-19. It offers its genome sequencing products to consumers online with plans to sell in food, drug, and mass retail stores. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.

www.prophaselabs.com

96

Full Time Employees

December 31

Fiscal Year Ends

Recent News: PRPH

View More

Performance Overview: PRPH

Trailing total returns as of 5/12/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

PRPH
56.97%
S&P 500 (^GSPC)
0.64%

1-Year Return

PRPH
93.52%
S&P 500 (^GSPC)
11.90%

3-Year Return

PRPH
94.80%
S&P 500 (^GSPC)
48.70%

5-Year Return

PRPH
78.33%
S&P 500 (^GSPC)
103.62%

Compare To: PRPH

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: PRPH

View More

Valuation Measures

Annual
As of 5/12/2025
  • Market Cap

    13.69M

  • Enterprise Value

    37.59M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.99

  • Price/Book (mrq)

    1.86

  • Enterprise Value/Revenue

    5.55

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -31.13%

  • Return on Equity (ttm)

    -174.58%

  • Revenue (ttm)

    6.77M

  • Net Income Avi to Common (ttm)

    -49.52M

  • Diluted EPS (ttm)

    -2.4200

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    678k

  • Total Debt/Equity (mrq)

    334.19%

  • Levered Free Cash Flow (ttm)

    5.02M

Research Analysis: PRPH

View More

Company Insights: PRPH

Research Reports: PRPH

View More

People Also Watch